Markets closed

Danaher Corporation

DHR · NYSE

Analyst Consensus

Buy

21 analysts

$204

Current

—

Low

$220

Average

—

High

Average target implies +7.89% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across all 21 analysts, with a stated mean target of $220; the supplied consensus does not provide low or high targets. Other aggregators place average targets at $228.91, $229.44, and $234.95, while AnaChart reports a $200-to-$270 range, showing a broad spread around the current $194.78 price. BofA's Michael Ryskin is explicitly identified as having the lowest named target in the supplied actions only by virtue of his $230 revision, while no source identifies the most bullish analyst; the highest published figure is $270 without a named analyst attached. The direction of the documented revision is negative: BofA cut its target from $270 to $230. The substantive disagreement concerns growth, profitability, and future P/E assumptions.

Rating Actions

No individual rating actions have been captured for DHRyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BENCHMARK COMPA

CITIGROUP

DEUTSCHE BK SEC

EDWARD JONES

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

KEYBANC CAP MKT

LEERINK PARTNRS

RAYMOND JAMES

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

UBS

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: DHR
Type: Stock
Sector: Industrials
Industry: Industrial Instruments For Measurement, Display, and Control
Exchange: NYSE

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges-helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

Key Issues

Bullish view

The company operates across life sciences, diagnostics, and bioprocessing, giving it exposure to pharmaceutical and biotechnology demand. Analysts still collectively rate the shares Buy, suggesting they see a path for growth to improve.

Bearish view

Recent analyst commentary cited more conservative assumptions for growth, profitability, and future P/E multiples. Fiscal 2025 net income also declined to $3.6 billion from $3.9 billion despite higher revenue.

Analyst Consensus

See all

Buy

21 analysts

$204

Current

—

Low

$220

Average

—

High

Average target implies +7.89% versus the current price.

Earnings History

BeatMissNo estimate

Danaher Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers